TY - JOUR
T1 - Deep Convolutional Generative Adversarial Network (dcGAN) Models for Screening and Design of Small Molecules Targeting Cannabinoid Receptors
AU - Bian, Yuemin
AU - Wang, Junmei
AU - Jun, Jaden Jungho
AU - Xie, Xiang Qun
N1 - Funding Information:
The authors would like to acknowledge the funding support to the Xie laboratory from the NIH NIDA (P30 DA035778A1 and R01DA025612) and DOD (W81XWH-16-1-0490) and the funding support to the J. Wang laboratory from NIH R01-GM079383.
Publisher Copyright:
Copyright © 2019 American Chemical Society.
PY - 2019/11/4
Y1 - 2019/11/4
N2 - A deep convolutional generative adversarial network (dcGAN) model was developed in this study to screen and design target-specific novel compounds for cannabinoid receptors. In the adversarial process of training, two models, the discriminator D and the generator G, are iteratively trained. D is trained to discover the hidden patterns among the input data to have the accurate discrimination of the authentic compounds and the "fake" compounds generated by G; G is trained to generate "fake" compounds to fool the well-trained D by optimizing the weights for matrix multiplication of data sampling. In order to determine the appropriate architecture and the input data structure for the involved convolutional neural networks (CNNs), the combinations of various network architectures and molecular fingerprints were explored. Well-developed CNN models including LeNet-5, AlexNet, ZFNet, and VGGNet were investigated. Four types of fingerprints, including MACCS, ECFP6, AtomPair, and AtomPair Count, were calculated to describe the small molecules with diverse structural characteristics. The limitation of generating fingerprints as output remains that the concrete molecular structures cannot be converted directly, while the generative models with convolutional networks provide promising opportunities to the screening of molecules and rational modifications afterward. This study demonstrated how computer-aided drug discovery could benefit from the recent advances in deep learning.
AB - A deep convolutional generative adversarial network (dcGAN) model was developed in this study to screen and design target-specific novel compounds for cannabinoid receptors. In the adversarial process of training, two models, the discriminator D and the generator G, are iteratively trained. D is trained to discover the hidden patterns among the input data to have the accurate discrimination of the authentic compounds and the "fake" compounds generated by G; G is trained to generate "fake" compounds to fool the well-trained D by optimizing the weights for matrix multiplication of data sampling. In order to determine the appropriate architecture and the input data structure for the involved convolutional neural networks (CNNs), the combinations of various network architectures and molecular fingerprints were explored. Well-developed CNN models including LeNet-5, AlexNet, ZFNet, and VGGNet were investigated. Four types of fingerprints, including MACCS, ECFP6, AtomPair, and AtomPair Count, were calculated to describe the small molecules with diverse structural characteristics. The limitation of generating fingerprints as output remains that the concrete molecular structures cannot be converted directly, while the generative models with convolutional networks provide promising opportunities to the screening of molecules and rational modifications afterward. This study demonstrated how computer-aided drug discovery could benefit from the recent advances in deep learning.
KW - CNN
KW - GAN
KW - cannabinoid receptor
KW - convolutional neural network
KW - deep learning
KW - drug design
KW - generative adversarial network
KW - machine learning
UR - http://www.scopus.com/inward/record.url?scp=85074267787&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074267787&partnerID=8YFLogxK
U2 - 10.1021/acs.molpharmaceut.9b00500
DO - 10.1021/acs.molpharmaceut.9b00500
M3 - Article
C2 - 31589460
AN - SCOPUS:85074267787
SN - 1543-8384
VL - 16
SP - 4451
EP - 4460
JO - Molecular Pharmaceutics
JF - Molecular Pharmaceutics
IS - 11
ER -